<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0FED1C47-231B-46E3-9C8D-2CE5528F10B1"><gtr:id>0FED1C47-231B-46E3-9C8D-2CE5528F10B1</gtr:id><gtr:name>The Karolinska Institute, Stockholm</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0FED1C47-231B-46E3-9C8D-2CE5528F10B1"><gtr:id>0FED1C47-231B-46E3-9C8D-2CE5528F10B1</gtr:id><gtr:name>The Karolinska Institute, Stockholm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7ADD968D-1D63-4687-B530-A7EC95C89DDF"><gtr:id>7ADD968D-1D63-4687-B530-A7EC95C89DDF</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>Joanna</gtr:otherNames><gtr:surname>Tabrizi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700877"><gtr:id>42FBDE39-5331-4635-B615-AC72540BA818</gtr:id><gtr:title>Cellular mechanisms of prion-mediated neurodegeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700877</gtr:grantReference><gtr:abstractText>The prion diseases are a group of rare but fatal diseases of the central nervous system (the brain in particular) for which there is at present no cure. They include CJD in humans, and scrapie and BSE in animals. These diseases can be acquired by ingestion of foodstuff containing the causative agent (called prion), for example contaminated meat and bone meal in the case of BSE, and products derived from cattle suffering from BSE in the case of variant CJD (vCJD). The BSE epidemic in the UK and the subsequent emergence of vCJD has made prion diseases a subject of intense research. BSE has no doubt transmitted to humans, but what is not known is what proportion of the exposed population will go on to develop vCJD. It is known that vCJD prions are transmitted by blood transfusion and currently there is concern that many of the UK population may be carrying vCJD prions which then may be transmitted through surgical procedures or blood transfusion. How prions cause damage to the nervous system is not known and the work in this study seeks to understand this. Once the key pathways have been defined then new drugs may be developed that act against those pathways. Other more common dementias such as Alzheimer?s disease and Parkinson?s disease may also share similar pathways to nerve cell death so understanding prion disease may also help identify treatment targets for these diseases.</gtr:abstractText><gtr:technicalSummary>Prion diseases are fatal neurodegenerative disorders whose pathogenesis is associated with a conformational rearrangement of the normal cellular prion protein (PrPC) to abnormal conformers (PrPSc). How prions cause neuronal death is not known. We have recently published in vivo and in vitro experimental data suggesting a novel mechanism for intracellular neurotoxicity mediated by oligomers of misfolded PrP. This grant seeks funding to continue this work to unravel the pathways of prion protein trafficking and degradation and how these may be altered to result in prion-mediated neurotoxicity. Understanding the cellular pathways of prion protein trafficking is fundamental to address how the misfolded prion protein causes neuronal dysfunction and death. We will also study prion neurobiology in our novel vCJD prion propagating cell line and determine the time course of prion degradation and prion-mediated neurodegeneration in ageing human neurons. Following these pathways in a neuronal model close to the human in vivo situation will have clear benefits for the development of therapeutics aimed at enhancing degradation or clearance of human vCJD prions. This cell line will therefore also be useful for screening human prion therapeutics as to date no human cell models exist in which to screen human prion therapies. Understanding cellular mechanisms of neurodegeneration is of fundamental scientific interest and importance. Neurodegenerative diseases represent one of the biggest health problems in our ageing society, and uncovering basic molecular mechanisms is fundamental for the development of rational therapeutics. Many neurodegenerative diseases such as AD, PD and HD occur as a result of misfolding and aggregation of key cellular proteins (protein conformational disorders). Prion disease is the prototypical protein misfolding neurodegenerative disorder as its pathogenesis is only associated with aberrant misfolding of a host cellular protein (the protein-only hypothesis). Therefore, advances in understanding the pathophysiology of prion disease has major implications for other neurodegenerative diseases associated with protein misfolding as it may help elucidate common cellular mechanisms in neurodegeneration. In addition, although prion diseases are rare, there are currently significant public health concerns in the UK re secondary transmission of vCJD (the human form of BSE) and whether a significant number of the UK population are indeed subclinical carriers of prion disease. Therefore the work in this project will both have relevance for the understanding of neurodegeneration per se as well as yield new cellular models for screening of human prion therapeutics.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>668115</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Professor Alfred Goldberg</gtr:description><gtr:id>8B5D0A5A-29D8-4523-B6D4-57086E3B6EAE</gtr:id><gtr:impact>Co-author of published paper in EMBO Journal, 2011 (Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry).</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Cell and Molecular Biology</gtr:department><gtr:description>Nico Dantuma Group</gtr:description><gtr:id>3EEFCEC3-81BC-4F1E-B86C-206FAEC9F0EA</gtr:id><gtr:impact>Sarah has a paper with Nico Dantuma. &amp;nbsp;She says she has been collaborating with him from 2006: M Kristiansen, P Deriziotis, D Dimcheff, GS. Jackson, H Ovaa, H Naumann, F Leeuwen, V Benito, AR Clarke, NP Dantuma, JL Portis, J Collinge, SJ Tabrizi.&amp;nbsp; Disease associated prion protein oligomers inhibit the 26S proteasome. Molecular Cell. 2007 Apr 27;26(2):175-88.&amp;nbsp;</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK (CRUK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Professor Giampietro Schiavo</gtr:description><gtr:id>A3EB1DC7-1D7F-4922-99D9-DE0CFB97D9F3</gtr:id><gtr:impact>Co-author of paper in Nature Communications, published in 2011 

Goold R, Rabbanian S, Sutton L, Andre R, Arora P, Moonga J, Clarke AR, Schiavo G, Jat P, Collinge J, Tabrizi SJ. Rapid cell-surface prion protein conversion revealed using a novel cell system. Nature Communications. 2011;2:281.

Goold R, McKinnon C, Rabbanian S, Collinge J, Schiavo G, Tabrizi SJ. Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane. Journal of Cell Science. 2013 Aug 15; 126(Pt 16):3552-62.</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents.</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Dr Maria Bjorkqvist</gtr:description><gtr:id>8F0F371C-A1BF-4627-9421-2F36C3F7883A</gtr:id><gtr:impact>18625748</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technion - Israel Institute of Technology</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:department>Faculty of Biology</gtr:department><gtr:description>Professor Michael Glickman</gtr:description><gtr:id>BDBC6BA7-3D60-49BD-803C-2211D77E8FC7</gtr:id><gtr:impact>Co-author of paper in EMBO Journal 2011 (Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition substrate entry).</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents.</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Professor Gillian Bates</gtr:description><gtr:id>14F78E0D-1554-4E0C-898A-589B9AAA371C</gtr:id><gtr:impact>Gill Bates - she has been collaborating with Gill Bates since 2000&amp;nbsp;and is co-applicant on another MRC grant with Gill Bates: 3 papers from 2006 are: Tsang T, Woodman B, McGloughlin G, Griffin J, Tabrizi SJ, Bates GP, Holmes E. Metabanomic Characterisation of the R6/2 Transgenic Mouse Model of Huntington's Disease by High-Resolution MAS 1H NMR spectroscopy. Journal of Proteome Research. 2006 Mar;5(3):483-92. Alexandra Zourlidou, Tali Gidalevitz , Mark Kristiansen , Ben Woodman, Dominic J. Wells, David S. Latchman, Jackie de Belleroche, S. J. Tabrizi, Richard I. Morimoto and Gillian P. Bates. Hsp27 overexpression in the R6/2 mouse model of Huntington's Disease: Chronic Neurodegeneration does not Induce Hsp27 Activation. Human Molecular Genetics. Epub 2007 Mar 14. 2007 May 1;16(9):1078-90. Annette Dalrymple, Edward J Wild, Richard Joubert, Kirupa Sathasivam, Maria Bj&amp;ouml;rkqvist, &amp;Aring;sa Peters&amp;eacute;n, Jeremy Isaacs, Mark Kristiansen, Gillian P Bates Blair R Leavitt, Geoff Keir, Malcolm Ward, S. J Tabrizi. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and candidate biomarkers Journal of Proteome Research. 2007 Jul;6(7):2833-40. 2008 -2011 Identification and Cross-validation of Early Stage Phenotypes in Mouse Models of Huntington's disease. Ref G0800846 - MRC - Models of Disease grant. Co-applicant with Professor Gillian Bates (PI) and Dr Michael Modeo (co-applicant). &amp;pound;910,736</gtr:impact><gtr:partnerContribution>I was co-applicant on this grant. As well as funding there was intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual Contribution and Reagents. Running in vivo aspects of the project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>HD Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DA00C7CA-EBDB-4007-B345-2384115AB4F3</gtr:id><gtr:impact>Articles of this nature serve to enhance engagement with my research

Positive feedback from patients and healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>25th International Symposium on ALS/MND, Brussels</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4297D458-7C0A-4C92-A5C6-492490EDB652</gtr:id><gtr:impact>Presented educational talk on HD to MNDA members</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHDI 10th Annual HD Therapeutics Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>009E8059-BBC3-47C5-BACD-66349DA3083B</gtr:id><gtr:impact>Presented talk on HD studies to researchers, healthcare practitioners and students.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in The Economist</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ECEB9D07-0B9B-4EC2-8402-90E7C8849DCB</gtr:id><gtr:impact>My work was summarised in an article in The Economist(http://www.economist.com/science/displaystory.cfm?story_id=9794864).

The article was picked up by national newspapers.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CAG Triplet Repeat Disorders, Tuscany, Italy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5E127832-8C93-4B4D-930E-8D326079BC34</gtr:id><gtr:impact>Presented talk on HD research to scientific peers and healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centre for Neuromuscular Diseases Seminar Series 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>77A9E4DE-1BB8-460D-96B0-2E2ED34A30CF</gtr:id><gtr:impact>Presented talk on therapeutic strategies in HD to students and professional practitioners alike. The talk generated lot's of interest and questions.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key Advances in Neurodegenerative Disorders Meeting, Royal Society of Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC1F122A-DB84-4A97-9631-0522A8CC149A</gtr:id><gtr:impact>Presented education talk on HD to healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brains Talk Seminar at Roche</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8BA174AF-D1CF-40F5-B1AA-557FFD12B19D</gtr:id><gtr:impact>Presented seminar on Hutington's Disease to Roche Pharmaceuticals to aid company strategic planning</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dendron Annual Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C8E5F624-9DF1-405E-9F7C-28588144CDC1</gtr:id><gtr:impact>Presenting information regarding the TRACK-HD Clinical Study

The organisers received positive feedback from participants from all over the world</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>14062</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European Huntington's Disease Network (Euro-HD)</gtr:department><gtr:description>Muscle pathology in HD as a source for biomarkers</gtr:description><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>921F4D27-B50A-4657-945E-F7AFCEC22E81</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>173200</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European Huntington's Disease Network (Euro-HD)</gtr:department><gtr:description>Euro-HD Registry Project Manager/European Huntington's Disease Network</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>AE0CFBF2-C8C2-4A5C-8CFA-A620EAE895E8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prevalence of HD in the UK</gtr:description><gtr:fundingOrg>Huntington's Disease Association England &amp; Wales (HDA)</gtr:fundingOrg><gtr:id>5879382E-6D08-4024-8856-DDA6EC010ED8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2950000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TRACK-HD</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>62951472-5833-473E-9184-7F933C74B0F8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dissecting myeloid and neuronal interactions in HD</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>CAB9D2A4-9BEE-45BC-A80E-F9C8576458CD</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>607672</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Celluar pathophysiology of prion mediated</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J003832/1</gtr:fundingRef><gtr:id>6945FDF3-9A33-46B8-BA2C-F415CD009998</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>151962</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Peripheral innate immune system activation in Huntington's disease and delineation of its importance for disease pathogenesis and biomarkers</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>9F16161A-81FC-40D3-8B8B-9F4AEE56D539</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>115561</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cure HD Initiative</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>F9702BB6-DD43-4E71-813A-B585C6829C06</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1568000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington's Disease by SEN0014196 (PADDINGTON). EU FP7 Health Call</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>576D82B6-CA50-43EF-872C-A72D67F83CA4</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>52000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The use of microarray gene profiling in HD blood to identify potential surrogate disease biomarkers as an aid to development to therapies</gtr:description><gtr:end>2007-07-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>B1B72F0E-FC2D-439F-806B-E0A84A717938</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>61390</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London</gtr:department><gtr:description>UCL/UCLH Comprehensive Biomedical Research Centre PhD Studentship/UCL/UCLH Comprehensive Biomedical Research Centre</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>5356C867-C950-4F46-B554-4F34E11D7889</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32400</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neuroendocrine profiling in Huntington's disease using meso-scale discovery</gtr:description><gtr:end>2007-07-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>C2CF3FEA-50C8-422D-BE75-F5F2F5958F5C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>151962</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cure HD Initiative</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>70817AE1-128E-4151-96F0-DA0BEC1E3769</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60442</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dissection of Peripheral and Central Myeloid Cell Function in HD</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>D320591B-2A2A-4D75-BD91-978DDD07F32D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88231</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain Research Trust PhD Studentship</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Brain Research Trust (BRT)</gtr:fundingOrg><gtr:id>58D95F6B-D4CF-4BA8-964E-AD5102E0BBF0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E1DC5F4-6C99-4302-ABDF-F881E2833B73"><gtr:id>0E1DC5F4-6C99-4302-ABDF-F881E2833B73</gtr:id><gtr:title>PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af3137ae30d800bbf896d7631ffa4d13"><gtr:id>af3137ae30d800bbf896d7631ffa4d13</gtr:id><gtr:otherNames>Wood-Kaczmar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B38D6AB7-381E-448F-995F-53063574D446"><gtr:id>B38D6AB7-381E-448F-995F-53063574D446</gtr:id><gtr:title>Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e27330390007f279cdbe4001d221e52"><gtr:id>4e27330390007f279cdbe4001d221e52</gtr:id><gtr:otherNames>Munsie L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38E10AFF-4371-40C8-9577-CAC29C6BDE5B"><gtr:id>38E10AFF-4371-40C8-9577-CAC29C6BDE5B</gtr:id><gtr:title>Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1db431be05506d4cf0ba9a69ddecabf4"><gtr:id>1db431be05506d4cf0ba9a69ddecabf4</gtr:id><gtr:otherNames>Deriziotis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A6C8D04-1BE2-4D5A-905B-C74E699A5A57"><gtr:id>6A6C8D04-1BE2-4D5A-905B-C74E699A5A57</gtr:id><gtr:title>Misfolded PrP and a novel mechanism of proteasome inhibition.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33cb2cd35605b1d2e4fb89262ae7aa6d"><gtr:id>33cb2cd35605b1d2e4fb89262ae7aa6d</gtr:id><gtr:otherNames>Andre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7785D7C6-2220-411C-B11F-25E1D2547F91"><gtr:id>7785D7C6-2220-411C-B11F-25E1D2547F91</gtr:id><gtr:title>Huntington's disease.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44b9220f49dff6ea9205d964cd07638a"><gtr:id>44b9220f49dff6ea9205d964cd07638a</gtr:id><gtr:otherNames>Novak MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C8E3D87F-B620-42B9-82F1-0F080B2DC798"><gtr:id>C8E3D87F-B620-42B9-82F1-0F080B2DC798</gtr:id><gtr:title>Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7CF6B357-DB3A-4802-907E-973FC85AFF54"><gtr:id>7CF6B357-DB3A-4802-907E-973FC85AFF54</gtr:id><gtr:title>Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f9e725ef6ddd749330cfec9a3d7caf2"><gtr:id>6f9e725ef6ddd749330cfec9a3d7caf2</gtr:id><gtr:otherNames>Bouchard J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5D9280F-53CF-4A35-814D-9606ACED79DC"><gtr:id>C5D9280F-53CF-4A35-814D-9606ACED79DC</gtr:id><gtr:title>Prion degradation pathways: Potential for therapeutic intervention.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b4a39284abbd940f6ef1be5b6468337"><gtr:id>9b4a39284abbd940f6ef1be5b6468337</gtr:id><gtr:otherNames>Goold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53D27200-8E8A-4DC5-8200-07BDD516C122"><gtr:id>53D27200-8E8A-4DC5-8200-07BDD516C122</gtr:id><gtr:title>Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19e574f7e92402bb2fe15089a7580366"><gtr:id>19e574f7e92402bb2fe15089a7580366</gtr:id><gtr:otherNames>McCourt AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1CFEC8E7-A730-420E-9810-305B12C19CE6"><gtr:id>1CFEC8E7-A730-420E-9810-305B12C19CE6</gtr:id><gtr:title>Huntington's disease.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44b9220f49dff6ea9205d964cd07638a"><gtr:id>44b9220f49dff6ea9205d964cd07638a</gtr:id><gtr:otherNames>Novak MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58145B15-DB3E-445F-B733-E42C6A37F22E"><gtr:id>58145B15-DB3E-445F-B733-E42C6A37F22E</gtr:id><gtr:title>A man with deteriorating ability to live independently.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44b9220f49dff6ea9205d964cd07638a"><gtr:id>44b9220f49dff6ea9205d964cd07638a</gtr:id><gtr:otherNames>Novak MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B65DDD05-43E3-49C6-AE53-5A7E3D7D48CE"><gtr:id>B65DDD05-43E3-49C6-AE53-5A7E3D7D48CE</gtr:id><gtr:title>Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2c089bd74059ce969aee77cd687de163"><gtr:id>2c089bd74059ce969aee77cd687de163</gtr:id><gtr:otherNames>Weiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/300C2A32-DC70-4822-A6FA-E43E9D6A4D68"><gtr:id>300C2A32-DC70-4822-A6FA-E43E9D6A4D68</gtr:id><gtr:title>Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b4a39284abbd940f6ef1be5b6468337"><gtr:id>9b4a39284abbd940f6ef1be5b6468337</gtr:id><gtr:otherNames>Goold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9630F37-F4C4-4A28-9807-99882FCFC6CE"><gtr:id>A9630F37-F4C4-4A28-9807-99882FCFC6CE</gtr:id><gtr:title>Rapid cell-surface prion protein conversion revealed using a novel cell system.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b4a39284abbd940f6ef1be5b6468337"><gtr:id>9b4a39284abbd940f6ef1be5b6468337</gtr:id><gtr:otherNames>Goold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD141BD9-21B4-47AC-A80E-D6E69A44EEF6"><gtr:id>AD141BD9-21B4-47AC-A80E-D6E69A44EEF6</gtr:id><gtr:title>Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a30e37c21a81f7625f8924ecdce9bed9"><gtr:id>a30e37c21a81f7625f8924ecdce9bed9</gtr:id><gtr:otherNames>Tr?ger U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7EB3FBFE-4330-4C24-BE2F-2AB655A5AD45"><gtr:id>7EB3FBFE-4330-4C24-BE2F-2AB655A5AD45</gtr:id><gtr:title>Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e025e0770ab6775f7402cc2ed94e2155"><gtr:id>e025e0770ab6775f7402cc2ed94e2155</gtr:id><gtr:otherNames>Dobson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2740D05C-7E0C-4314-BE94-538B1D3C2BD8"><gtr:id>2740D05C-7E0C-4314-BE94-538B1D3C2BD8</gtr:id><gtr:title>PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7fe26393ce1a826c37d2c03b54270978"><gtr:id>7fe26393ce1a826c37d2c03b54270978</gtr:id><gtr:otherNames>Gandhi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/751D0470-BF1F-4795-9ED6-448A00C1D743"><gtr:id>751D0470-BF1F-4795-9ED6-448A00C1D743</gtr:id><gtr:title>Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72f6f7a612489664bd7da0da0315c636"><gtr:id>72f6f7a612489664bd7da0da0315c636</gtr:id><gtr:otherNames>McKinnon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D76F7E08-94AB-4352-B4C3-0BE4970C6CCD"><gtr:id>D76F7E08-94AB-4352-B4C3-0BE4970C6CCD</gtr:id><gtr:title>HTT-lowering reverses Huntington's disease immune dysfunction caused by NF?B pathway dysregulation.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a30e37c21a81f7625f8924ecdce9bed9"><gtr:id>a30e37c21a81f7625f8924ecdce9bed9</gtr:id><gtr:otherNames>Tr?ger U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E69BCB04-1662-41E1-9D1F-5E699830A59A"><gtr:id>E69BCB04-1662-41E1-9D1F-5E699830A59A</gtr:id><gtr:title>Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c91c19e9fd174710fd50739e4f6ada4"><gtr:id>7c91c19e9fd174710fd50739e4f6ada4</gtr:id><gtr:otherNames>Miller JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91DA757D-B2C7-40CC-88DC-7153F44E0C90"><gtr:id>91DA757D-B2C7-40CC-88DC-7153F44E0C90</gtr:id><gtr:title>Disease-associated prion protein oligomers inhibit the 26S proteasome.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0b2c9e84a2d8cce8f9ac2c9beec0c386"><gtr:id>0b2c9e84a2d8cce8f9ac2c9beec0c386</gtr:id><gtr:otherNames>Kristiansen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7BE3953-C221-417B-805B-DB570FAA126A"><gtr:id>D7BE3953-C221-417B-805B-DB570FAA126A</gtr:id><gtr:title>Harnessing immune alterations in neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e2261a93a33349b25ecf277129ca5064"><gtr:id>e2261a93a33349b25ecf277129ca5064</gtr:id><gtr:otherNames>Bj?rkqvist M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D88D60DC-625E-41E8-9FED-472D58B41151"><gtr:id>D88D60DC-625E-41E8-9FED-472D58B41151</gtr:id><gtr:title>A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e2261a93a33349b25ecf277129ca5064"><gtr:id>e2261a93a33349b25ecf277129ca5064</gtr:id><gtr:otherNames>Bj?rkqvist M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5042F592-DAD4-4D65-A029-EB542861F551"><gtr:id>5042F592-DAD4-4D65-A029-EB542861F551</gtr:id><gtr:title>The ubiquitin-proteasome system in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72f6f7a612489664bd7da0da0315c636"><gtr:id>72f6f7a612489664bd7da0da0315c636</gtr:id><gtr:otherNames>McKinnon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A87BD71B-2DD9-4389-9C41-470FAEF22058"><gtr:id>A87BD71B-2DD9-4389-9C41-470FAEF22058</gtr:id><gtr:title>Prions and the proteasome.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1db431be05506d4cf0ba9a69ddecabf4"><gtr:id>1db431be05506d4cf0ba9a69ddecabf4</gtr:id><gtr:otherNames>Deriziotis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B87DCA5D-BA7C-469F-878E-46E38CF55D33"><gtr:id>B87DCA5D-BA7C-469F-878E-46E38CF55D33</gtr:id><gtr:title>The ubiquitin-proteasome system in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72f6f7a612489664bd7da0da0315c636"><gtr:id>72f6f7a612489664bd7da0da0315c636</gtr:id><gtr:otherNames>McKinnon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700877</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>